07/31/2015 - 2:06pm

In late July, the Government Accountability Office released a report on how the lack of effective communications between the Drug Enforcement Agency and both pharmaceutical distributors and chain pharmacy headquarters has impacted legitimate access to pain medicines. "The agency’s report further validates the need for bipartisan, bicameral legislation," according to NACDS.

07/30/2015 - 3:24pm

Par Pharmaceutical Thursday announced that it has begun shipping the authorized generic version of Megace ES (megestrol acetate, USP) oral suspension.

07/30/2015 - 12:28pm

McKesson on Thursday reported increased revenues for the first quarter, which ended June 30. At $47.5 billion, revenues were up 9%, compared with $43.5 billion a year ago. First-quarter earnings per diluted share from continuing operations was $2.50 compared with $1.76 a year ago.

07/29/2015 - 10:48am

Hikma Pharmaceuticals on Wednesday announced its acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane (together, “Roxane” — an American specialty generics company) from Boehringer Ingelheim for about $2.65 billion.

07/28/2015 - 11:46am

Voters from all political parties support sunshine legislation that would make promote transparency in generic prescription drug payments by pharmacy benefit manager corporations, according to a national survey from the National Community Pharmacists Association released Tuesday.

07/28/2015 - 11:00am

Sandoz on Tuesday announced the launch of a generic version of AstraZeneca’s Pulmicort Respules (budesonide inhalation suspension) in 1-mg strength. Sandoz expects to have 180-day generic drug marketing exclusivity for the 1-mg strength.

07/28/2015 - 6:26am

A GAO report released Monday suggests that the Drug Enforcement Agency should take steps to improve communications with pharmacists, manufacturers. 

07/27/2015 - 4:50pm

The GpHA and Biosimilars Council have published their objections to the Trans-Pacific Partnership trade agreement to the pages of the New York Times. 

07/27/2015 - 9:31am

In a move that will reshape the generic pharmaceuticals landscape, Teva announced Monday that it would be acquiring Allergan Generics for $40.5 billion.